A phase II trial to assess the impact of b2 adrenergic blockade in immune checkpoint inhibitor (ICI)- refractory metastatic triple negative breast cancer (mTNBC)

被引：0
|
作者：
Gandhi, Shipra [1 ]
Roy, Arya Mariam [1 ]
Minderman, Hans [1 ]
Rosario, Spencer [1 ]
Repasky, Elizabeth A. [1 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1141
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)
    Barroso-Sousa, Romualdo
    Forman, Juliet
    Weber, Zachary T.
    Collier, Katherine
    Kao, Katrina Z.
    Richardson, Edward T., III
    Keenan, Tanya
    Cohen, Ofir
    Manos, Michael P.
    Brennick, Ryan C.
    Ott, Patrick
    Hodi, F. Steve
    Dillon, Deborah A.
    Lin, Nancy U.
    Van Allen, Eliezer E.
    Rodig, Scott
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Wu, Catherine J.
    Stover, Daniel
    Wagle, Nikhil
    Shukla, Sachet
    Tolaney, Sara
    CANCER RESEARCH, 2021, 81 (04)
  • [2] Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).
    Veitch, Zachary William Neil
    Cescon, David W.
    Elston, Sawako
    Lien, Scott
    Yang, Cindy
    Wang, Ben X.
    Berman, Hal K.
    Butler, Marcus O.
    Amir, Eitan
    Elser, Christine
    Hakgor, Sevan
    Giesler, Amanda
    Pugh, Trevor John
    Ohashi, Pamela S.
    Siu, Lillian L.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC)
    Keenan, Tanya E.
    Tan-Wasielewski, Zhenying
    Trippa, Lorenzo
    Kochupurakkal, Bose
    Guerriero, Jennifer L.
    Tahara, Rie K.
    Winship, Grace
    Osmani, Wafa
    Andrews, Chelsea
    Conway, Jake R.
    He, Meng X.
    Pastorello, Ricardo
    Tracy, Adam
    Godin, Robert E.
    Overmoyer, Beth A.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Shapiro, Geoffrey I.
    Van Allen, Eliezer M.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [4] A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
    Sun, Kai
    Xu, Yitian
    Zhang, Licheng
    Niravath, Polly
    Darcourt, Jorge
    Patel, Tejal
    Teh, Bin S.
    Farach, Andrew M.
    Guerrero, Carlo
    Mathur, Sunil
    Sultenfuss, Mark A.
    Gupta, Nakul
    Schwartz, Mary R.
    Haley, Susan L.
    Nair, Sindhu
    Li, Xiaoxian
    Nguyen, Thi Truc Anh
    Butner, Joseph D.
    Ensor, Joe
    Mejia, Jaime A.
    Mei, Zhuyong
    Butler, E. Brian
    Chen, Shu-Hsia
    Bernicker, Eric H.
    Chang, Jenny C.
    CLINICAL CANCER RESEARCH, 2022, 28 (20) : 4392 - 4401
  • [5] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
    Obeid, E.
    Miller, K. D.
    Sparano, J. A.
    Blackwell, K.
    Goldstein, L. J.
    CANCER RESEARCH, 2017, 77
  • [6] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC)
    Barroso-Sousa, Romualdo
    Trippa, Lorenzo
    Li, Tianyu
    Keenan, Tanya E.
    Winship, Grace
    Andrews, Chelsea
    Osmani, Wafa
    Overmoyer, Beth
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Duda, Dan G.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [7] Phase II trial of selinexor for metastatic triple negative breast cancer
    Han, H. S.
    Ismail-Khan, R.
    Carney, D.
    Extermann, M.
    Hogue, D.
    Soliman, H.
    Loftus, L.
    Lee, J. K.
    Sullivan, D.
    CANCER RESEARCH, 2017, 77
  • [8] A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC).
    Barroso-Sousa, Romualdo
    Guo, Hao
    Barry, William Thomas
    Winship, Grace
    Overmoyer, Beth
    Duda, Dan G.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit
    Barroso-Sousa, Romualdo
    Forman, Juliet
    Collier, Katharine
    Weber, Zachary T.
    Jammihal, Tejas R.
    Kao, Katrina Z.
    Richardson, Edward T., III
    Keenan, Tanya
    Cohen, Ofir
    Manos, Michael P.
    Brennick, Ryan C.
    Ott, Patrick A.
    Hodi, F. Stephen
    Dillon, Deborah A.
    Attaya, Victoria
    O'Meara, Tess
    Lin, Nancy U.
    Van Allen, Eliezer M.
    Rodig, Scott
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Wu, Catherine J.
    Wagle, Nikhil
    Stover, Daniel G.
    Shukla, Sachet A.
    Tolaney, Sara M.
    JCO PRECISION ONCOLOGY, 2022, 6
  • [10] A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
    Lander, Eric Michael
    Lehmann, Brian David
    Shah, Payal D.
    Dees, Elizabeth Claire
    Ballinger, Tarah Jean
    Pohlmann, Paula Raffin
    Santa-Maria, Cesar Augusto
    Shyr, Yu
    Mayer, Ingrid A.
    Park, Ben Ho
    Pietenpol, Jennifer A.
    Abramson, Vandana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345